NCT04623086View on ClinicalTrials.gov

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

PHASE4CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

September 7, 2022

Study Completion Date

December 31, 2023

Conditions
Type 1 Diabetes
Interventions
DRUG

Insulin Degludec

Insulin Degludec injection

DRUG

Insulin Glargine

Insulin Glargine injection

DRUG

Placebo

9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection

Trial Locations (1)

98109

University of Washington Medicine Diabetes Institute at South Lake Union, Seattle

All Listed Sponsors
lead

University of Washington

OTHER

NCT04623086 - Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose | Biotech Hunter | Biotech Hunter